Want to see SE:SYNACT full AI Analyst Report?
Top Page
SynAct Pharma AB
(SYNACT)
Select Model
Select Model
Rating:49Neutral
Price Target:
kr17.50
▼(-9.98% Downside)
Action:Reiterated
Date:08/21/26
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and sustained cash burn despite a low-debt balance sheet). Technicals add modest support with price above major moving averages and a positive MACD, while valuation remains unattractive/unclear given negative earnings and no dividend yield data.
Positive Factors
Low leverage
The very low debt burden reduces interest and refinancing pressure while preserving financial flexibility relative to a highly leveraged biotech. A sizable equity base provides a stronger starting position for funding development activities, although ongoing losses still require careful capital management.
Negative Factors
No commercial revenue
Without recurring product revenue, SynAct lacks an operating cash engine to fund research and clinical trials. Its financial outlook therefore depends heavily on successful development milestones, future partnering, or additional capital rather than on established customer demand and repeat sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
The very low debt burden reduces interest and refinancing pressure while preserving financial flexibility relative to a highly leveraged biotech. A sizable equity base provides a stronger starting position for funding development activities, although ongoing losses still require careful capital management.
Read all positive factors
SynAct Pharma AB (SYNACT) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr1.01B
Dividend YieldN/A
Average Volume (3M)210.73K
Price to Earnings (P/E)―
Beta (1Y)0.06
Revenue GrowthN/A
EPS Growth1.42%
CountrySE
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.97
Shares Outstanding53,330,242
10 Day Avg. Volume338,892
30 Day Avg. Volume210,733
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)6.78
Price to Sales (P/S)0.00
P/FCF Ratio-11.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.49
Revenue Forecast (FY)N/A
SynAct Pharma AB Business Overview & Revenue Model
Company Description
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently ...
How the Company Makes Money
SynAct Pharma is a clinical-stage biopharmaceutical company and, based on publicly available information, it does not appear to have a marketed product generating recurring commercial sales; therefore, its business model is primarily funding-drive...
SynAct Pharma AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
29
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -617.00K | -778.00K | -1.06M | -88.00K |
| EBITDA | -113.35M | -116.52M | -15.40M | -222.70M | -105.71M | -76.62M |
| Net Income | -106.14M | -110.83M | -82.40M | -215.81M | -99.20M | -69.30M |
Balance Sheet | ||||||
| Total Assets | 208.24M | 220.52M | 270.52M | 228.02M | 142.60M | 38.37M |
| Cash, Cash Equivalents and Short-Term Investments | 14.23M | 53.41M | 61.21M | 62.40M | 108.25M | 24.00M |
| Total Debt | 929.00K | 1.81M | 1.88M | 637.00K | 2.06M | 3.09M |
| Total Liabilities | 36.57M | 50.23M | 56.35M | 51.83M | 16.08M | 17.50M |
| Stockholders Equity | 171.67M | 170.29M | 214.17M | 176.19M | 126.52M | 20.87M |
Cash Flow | ||||||
| Free Cash Flow | -82.67M | -97.33M | -89.20M | -100.18M | -117.56M | -65.00M |
| Operating Cash Flow | -117.21M | -97.33M | -89.20M | -100.18M | -117.56M | -65.00M |
| Investing Cash Flow | -13.89M | 0.00 | 0.00 | 370.00K | 27.00K | -6.00K |
| Financing Cash Flow | 77.01M | 90.46M | 87.41M | 53.98M | 200.71M | 74.32M |
SynAct Pharma AB Technical Analysis
Negative
19.44
Price Trends
19.28
Negative
17.31
Positive
18.63
Positive
Market Momentum
-0.01
Positive
48.79
Neutral
39.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SYNACT, the sentiment is Negative. The current price of 19.44 is below the 20-day moving average (MA) of 19.44, above the 50-day MA of 19.28, and above the 200-day MA of 18.63, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 48.79 is Neutral, neither overbought nor oversold. The STOCH value of 39.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SYNACT.
SynAct Pharma AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr447.16M | 2.33 | 63.09% | ― | ― | ― | |
56 Neutral | kr4.12B | -5.15 | ― | ― | -3.57% | 8.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr1.01B | -9.62 | -58.12% | ― | ― | 1.42% | |
45 Neutral | kr1.64B | -1.70 | -23.22% | ― | -195.45% | -223.22% | |
43 Neutral | kr1.49B | -3.01 | -99.58% | ― | -87.22% | -70.29% | |
43 Neutral | kr114.67M | -11.04 | -93.01% | ― | ― | 54.60% |
* Healthcare Sector Average
SE:SYNACT
SynAct Pharma AB
18.96
0.70
3.83%
SE:HNSA
Hansa Biopharma AB
40.50
11.00
37.29%
SE:BINV
BioInvent International AB
22.70
-4.80
-17.45%
SE:FLERIE
InDex Pharmaceuticals Holding AB
18.00
-18.31
-50.43%
SE:ACTI
Active Biotech AB
4.35
-8.76
-66.81%
SE:CANTA
Cantargia AB
1.59
-1.06
-40.04%
SynAct Pharma AB Corporate Events
SynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals
Sep 7, 2026
SynAct Pharma has released further analysis from its Phase 2b ADVANCE study of resomelagon in treatment-naïve rheumatoid arthritis patients, reinforcing earlier positive EXPAND data and supporting Phase 3 development. The company plans to ref...
SynAct Pharma Executives Sell Shares to Cover Danish Tax Liabilities
Sep 3, 2026
SynAct Pharma has disclosed that its chief executive officer, Jeppe Øvlesen, and chief scientific officer, Thomas Jonassen, have sold portions of their shareholdings in the company. The disposals were executed via their associated entities, Q...
SynAct Pharma Expands Resomelagon’s Potential With New Preclinical Inflammation Data
Aug 28, 2026
SynAct Pharma will present new preclinical data on its Phase 3-ready resomelagon candidate at the 17th World Congress of Inflammation 2026 in Brazil, highlighting a distinct pro-resolution mechanism of action for inflammatory and infectious diseas...
SynAct Pharma Details 2026 First-Half Progress in Inflammatory Disease R&D
Aug 20, 2026
SynAct Pharma has released its interim report for January to June 2026, highlighting research and development progress in inflammatory diseases and providing operational and financial updates to stakeholders. The report underscores the companyR...
SynAct Pharma strikes first resomelagon commercial deal in Brazil’s dengue market
Aug 19, 2026
SynAct Pharma has signed a term sheet with Brazilian drug maker Hipolabor Farmacêutica for a co-development and commercialization partnership around resomelagon to treat dengue and other viral infections in Brazil. The structure allows SynAct...
SynAct Pharma Wins Key US Patent Ruling on Resomelagon Tablet Formulation
Aug 5, 2026
SynAct Pharma AB has secured a favorable ruling from the U.S. Patent Trial and Appeal Board on a patent application covering an immediate-release tablet formulation of its lead drug candidate, resomelagon. The decision confirms that developing a r...
SynAct Pharma Secures New Financing Facility to Bolster Phase III Readiness
Jul 20, 2026
SynAct Pharma has secured access to a new strategic financing facility of up to SEK 100 million and has initially drawn SEK 50 million through the issuance of convertible loans. The move strengthens the biotech’s balance sheet, broadens its ...
SynAct preclinical data point to osteoarthritis potential for resomelagon
Jul 9, 2026
SynAct Pharma AB reported early preclinical data indicating that its drug candidate resomelagon (AP1189) can reduce inflammation, joint damage and pain in a mouse model of osteoarthritis, a condition affecting hundreds of millions globally. The fi...
SynAct Pharma draws heightened partner interest as ADVANCE data boost resomelagon’s strategic appeal
Jun 29, 2026
SynAct Pharma reported a marked increase in interest from pharmaceutical companies and specialized healthcare investors after presenting positive ADVANCE study results for its lead candidate resomelagon at the BIO International Convention in San D...
SynAct Pharma Leadership Locks Up Shares Through 2026 to Signal Long-Term Confidence
Jun 15, 2026
SynAct Pharma’s entire shareholding board and management team have entered into lock-up agreements, pledging not to sell or otherwise dispose of their shares and related securities until the end of 2026. The move is presented as a strong sig...
SynAct’s RA Drug Resomelagon Delivers Positive Phase 2b Data, Fuels Partnering Push
Jun 15, 2026
SynAct Pharma reported Phase 2b ADVANCE trial data showing that its oral candidate resomelagon, added to methotrexate, produced strong clinical responses and biomarker improvements in newly diagnosed, highly active rheumatoid arthritis patients, w...
SynAct extends U.S. patent exclusivity for lead RA therapy resomelagon to 2044
Jun 12, 2026
SynAct Pharma AB has secured a key U.S. patent for its lead candidate resomelagon (AP1189), which will now run until July 2044 after a Patent Term Adjustment of 742 days. The patent underpins the company’s strategy around developing resomela...
SynAct Pharma AGM Confirms No Dividend and Renews Mandate for New Share Issues
Jun 11, 2026
SynAct Pharma AB’s 2026 Annual General Meeting approved the 2025 financial statements, confirmed that no dividend will be paid with profits carried forward, and granted discharge from liability to the board and CEO, underscoring a capital-pr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.